Form 4: Eliem Therapeutics COO Brett Kaplan Acquires Stock Options and Restricted Stock Units

Chief Operating Officer of Eliem Therapeutics, Brett Kaplan, reports the acquisition of stock options and restricted stock units in the company.

Summary

• Brett Kaplan, the Chief Operating Officer of Eliem Therapeutics, acquired 465,000 stock options and 77,500 restricted stock units (RSUs) on August 26, 2024.
• The stock options have an exercise price of $5.95 and vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments.
• The RSUs also vest over four years, with 25% vesting on each of the first four anniversaries of the grant date.
• Both the stock options and RSUs are subject to Kaplan's continued service with the company.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, suggesting confidence in the company's future performance. The grant of equity aligns management's interests with shareholders, which is generally viewed positively.

Positives

• The granting of stock options and RSUs to the COO aligns his interests with those of the shareholders, incentivizing him to drive company performance.
• The vesting schedules encourage long-term commitment from the COO.

Future Outlook

The document does not contain any specific forward-looking statements beyond the vesting schedules of the stock options and RSUs.

Industry Context

Granting stock options and RSUs is a common practice in the biotechnology industry to attract and retain key executives and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Biogen, and Gilead Sciences routinely grant stock options and RSUs to their executives as part of their overall compensation strategy.
• The vesting schedules described in the document are typical for such grants, aligning with industry norms.

Stakeholder Impact

• Shareholders may view the grant of stock options and RSUs positively, as it aligns management's interests with the company's long-term success.
• Employees may be motivated by the fact that executives are incentivized to improve company performance.

Key Dates